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required, that might reduce the risk 
of transmission to others, as is being 
attempted in South Africa.2
As case detection and treatment 
for MDR tuberculosis is scaled up 
internationally,3 how to care for pati-
ents who have exhausted all treatment 
options with existing second-line drugs 
will become increasingly important. 
Currently, no third-line treatment 
for tuberculosis exists. Until newer 
drugs become available, we will need 
to care for such patients in a manner 
that balances the risk of ongoing 
transmission with individual human 
rights. The health system must still 
support patients in whom treatment 
has failed. The provision of home-
based palliative care, for example, is 
likely to be more humane and less 
costly to health services compared with 
involuntary detention.4
Although a small proportion of 
patients might realistically be classiﬁ ed 
as recalcitrant, and legal means may 
be necessary to restrict transmission, 
we feel that every eﬀ ort should be 
made to support patients, either to 
continue treatment if they so wish, 
or to live out the remainder of their 
lives in a manner that minimises the 
risk of transmission to others.5 In this 
case, the threat of incarceration is also 
likely to further reduce the chances 
that this patient will be located. We 
feel that such patients should not be 
managed by an automatic resort to 
legal coercion.
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MDR tuberculosis and 
non-compliance with 
therapy
Suheir Ereqat and colleagues1 
described a patient with multidrug-
resistant (MDR) tuberculosis who has 
defaulted after 2 years of treatment 
and is untraceable. They lament the 
absence of legal means by which this 
patient might be forced to return to 
Palestine and continue treatment. 
We believe this approach puts a 
mistaken emphasis on legal coercion 
that is neither eﬀ ective nor humane. 
If this patient failed treatment, as it 
would seem, an understanding of the 
reasons for treatment failure would 
be important. Did the patient have 
a history of defaulting treatment 
previously and, if so, what counselling 
did this patient receive? Aside from 
directly observed treatment, what 
support was oﬀ ered to empower him 
to continue his treatment? What 
further treatment do the authors 
suggest should be prescribed? Forcing 
a patient to continue an ineﬀ ective, 
toxic regimen that results in no clear 
beneﬁ t is clearly diﬃ  cult. For patients 
like these, attention could be more 
usefully directed at exploring possible 
regimens with better chances of 
cure; and securing an appropriate 
environment, such as supportive 
accommodation with access to 
counselling and palliative care when 
Authors’ Reply
We thank Helen Cox and colleagues for 
their comments, but point out that we 
do not disagree with them. Health is a 
human right that should be guaranteed 
through legal and social policies. 
We endeavoured in our letter1 to ask 
questions, not to propose an answer. 
Naturally the Palestinian Health 
Authority made all eﬀ orts to keep 
the patient in therapy. Our letter was 
directed at a recalcitrant patient, one 
who has had all counselling suggested 
and who then disappeared and thus 
refused further therapy.  What are our 
obligations as doctors in this case and 
what do we do if the patient goes to 
a diﬀ erent country? As multidrug-
resistant microbes are becoming an 
increasing health and community 
problem, should thought be given to 
making some such infections notiﬁ able 
diseases, as is done in Australia for 
various other diseases?2 Such a move 
could solve many problems and allow 
some control of patients.
Cox and colleagues state that no new 
third-line treatment for tuberculosis 
exists, but happily the situation is not 
quite that bleak.3,4 We would pose 
the question: if this individual were a 
teacher of young children, would he 
be allowed to work? And if he moved 
and left treatment, what are the legal 
obligations and constraints on his 
physicians or the relevant health author-
ity to notify people at his destination 
or issue a general warning? We too 
believe that any form of control should 
not aﬀ ect the patient’s dignity, but the 
question of compulsory isolation for 
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showed increased resistance rates to 
ceftazidime during SDD.4
At face value, this study shows that 
in the short term, during ICU stay, 
patients might beneﬁ t from SDD. The 
questions about the eﬀ ects in the long 
term, for patients and for the hospital 
environment, remain unanswered.
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led to baseline diﬀ erences between 
groups and might have also biased 
their recent analysis:1 diagnostic 
investigations, such as microbiological 
cultures, might have been diﬀ erent 
in patients known to receive SDD. 
Protocols in the SDD and the control 
groups diﬀ ered between the various 
ICUs: endotracheal cultures were 
obtained on a regular basis between 
admission and discharge from all 
patients in the SDD group, but not 
from all patients on standard therapy.1 
Thus, colonisation with highly 
resistant microorganisms (HRMO) 
on admission could not always be 
excluded in the control group, because 
of the protocol rule that patients with 
the same species of HRMO isolated 
during the ﬁ rst 3 days and after the 
third day were not classiﬁ ed as having 
ICU-acquired HRMO. This rule was 
applied for patients with cefotaxime-
resistant and tobramycin-resistant 
Gram-negative bacteria. The lower 
frequency of culturing during the 
ﬁ rst 3 days of admission on standard 
therapy compared with SDD precludes 
the recognition of colonisation on 
admission (and hence exclusion as 
ICU acquired) in the control group, 
which implies bias in favour of the 
SDD group. The authors mention 
that the ﬁ ndings did not diﬀ er in 
the ﬁ rst 3 days during the control 
period between the ICUs that took 
cultures with diﬀ erent frequencies. 
This was a post-hoc ﬁ nding, based on 
the diﬀ erences in the protocol in the 
various ICUs that participated in the 
same trial; the conclusion of the paper 
depends on this casuistic ﬁ nding, 
but there are no data provided for 
readers. 
The frequency of colonisation of 
patients treated with cefotaxime, 
tobramycin, and colistin, with micro-
organisms resistant to these same 
antibiotics, was lower than in untreated 
patients. This ﬁ nding deﬁ es micro-
biological experience. The authors 
do not discuss this singularity even 
though this ﬁ nding partly contradicts 
earlier ﬁ ndings in the same trial, which 
multidrug-resistant cases that might 
represent a risk of contamination to 
society remains open.
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Resistance after 
selective 
decontamination 
Anne Marie de Smet and colleagues1 
report that selective digestive tract 
decontamination (SDD) protects 
against acquisition of resistant 
microorganisms in patients in 
intensive-care units (ICUs). In their 
previous publication, they described 
how the cluster design hampered 
concealment of randomisation: 
physicians knew which treatment 
their patients would receive.2 Because 
only about one third of patients 
admitted to the ICU received SDD, in 
the control period doctors selected 
patients who “would have received 
SDD if this had been the treatment 
period.”2,3 This method of selection 
We would like to highlight four aspects 
of the study presented by Anne Marie 
de Smet and colleagues,1 which we 
believe cast doubt on their conclusion. 
First, the frequency of blood 
culture collections in the selective 
digestive tract decontamination 
(SDD) and selective oropharyngeal 
decontamination (SOD) groups was 
not less than in the standard care 
group,1 which suggests that the 
clinical suspicion of sepsis was similar 
in the three groups and that SOD and 
SDD simply suppressed the growth of 
bacteria in the blood cultures.
Second, screening with endotracheal 
aspirate cultures within 3 days of 
entry was undertaken for only 35% of 
patients in the standard care group 
